With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?

With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?

With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Peter Lio, MD

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois